Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02974270
Recruitment Status : Unknown
Verified November 2016 by Cheol Woo Ko, Kyungpook National University Hospital. Recruitment status was: Recruiting
First Posted : November 28, 2016
Last Update Posted : November 28, 2016
Kyungpook National University Hospital
Information provided by (Responsible Party):
Cheol Woo Ko, Kyungpook National University Hospital
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
up to 9 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Child diagnosed with CPP who has a peak-stimulated Lutenizing Hormone(LH) concentration over 5 IU/liter before initiation of therapy
Chronological age(CA) at the appearance of pubertal changes less than 8 years in girls and less than 9 years in boys.
Tanner stage ≥2
Advanced bone age (Bone Age/Chronological Age >1.1)
Able to have the signed written informed consent provided by the patients' parents or legal guardians prior to any study-related procedures
Patient with a peripheral precocious puberty: extrapituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex steroids secretion
Patient with a cerebral tumor requiring a neurosurgery or cerebral irradiation known chronic disease of underlying medical condition